After jumping into action following the attacks of September 11th, John found himself looking to make more of a direct impact on patients and families - ultimately leading him to a fulfilling career at Daiichi Sankyo. bit.ly/4vQHdJK #WhereCraftMeets
Daiichi Sankyo US
1,264 posts
Daiichi Sankyo US
@DaiichiSankyoUS
We create life-changing solutions for patients. See our guidelines: bit.ly/4fLkZS8
- #ASCO26NEWS: Throughout @ASCO, we will present more than 25 abstracts across our oncology portfolio in multiple cancers. Click the image to learn more about the specific presentations. bit.ly/49tqRhD
- #BREAKINGNEWS: The FDA has approved our DXd ADC for the first-line treatment of certain adult patients with unresectable or metastatic triple negative breast cancer in collaboration with @AstraZenecaUS. Click to learn more: bit.ly/4utn6kJ
- Oncology demands more than science. It calls for people who understand what's at stake. 🔍 See how John’s personal experience with cancer and our collective purpose drives patient care: bit.ly/4w9TXMOs
00:00 - #BREAKINGNEWS: Our DXd #ADC has been granted two new indication approvals by the FDA for the neoadjuvant and for the adjuvant treatment of adult patients w/ #HER2 positive early-stage breast cancer w/ @AstraZenecaUS. Click to learn more: bit.ly/4dfNdW4
- Today we announced our 2035 Vision and Five-Year Business Plan to be recognized as a trusted healthcare innovator transforming the lives of people through science and technology. Learn more: bit.ly/4noHbpJ #DaiichiSankyoVision2035
- Starting her career as a registered nurse, Michele uses her experience working with patients and their families to think holistically about new medicine development as an R&D leader at Daiichi Sankyo. bit.ly/4tMkFZI #WhereCraftMeets
- #BREAKINGNEWS: The FDA has accepted and granted Priority Review for the BLA for our investigational DXd ADC in certain adult patients with ES-SCLC in collaboration with @Merck. Click here to learn more: bit.ly/4tib0dx #SCLC #CancerResearch
- #BREAKINGNEWS: The FDA has granted Priority Review for the sBLA for our HER2-directed DXd ADC as a post-neoadjuvant treatment in patients with HER2-positive early breast cancer in collaboration with @AstraZenecaUS. Click to learn more: bit.ly/3PriPyk
- Gynecologic cancers are often difficult to detect early, making deeper biological understanding & new treatment approaches critical. Read how we’re evaluating the potential of HER2-directed therapies in #EndometrialCancer & #OvarianCancer: bit.ly/4rT9Ep1
- Daiichi Sankyo announces that Dr. Ken Takeshita will step down as Head of Global R&D effective April 1, 2026. We thank Ken for his transformative leadership and welcome Dr. John Tsai as he steps in to advance our oncology pipeline and next generation innovation.
- From leadership development to transformative cancer medicines, our enterprise approach earned the first Global Impact Award Honorable Mention from @HBAnet. Thank you to our global teams. #DSProud #AscendWithHBAToday, we are thrilled to announce @DaiichiSankyoUS as the winner of the 2026 HBA Global Impact Award Honorable Mention Distinction! Read the full announcement here: hbanet.org/news/2026/02/5…
00:00 - #BREAKINGNEWS: @DaiichiSankyoUS has initiated a phase 1/2 trial evaluating our CD37 directed DXd ADC in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Learn more: bit.ly/4qcdVSD
